Percheron Therapeutics Limited
@PercheronTxL
Followers
217
Following
14
Media
16
Statuses
101
Biotechnology company developing and commercializing antisense pharmaceuticals for large unmet markets in rare disease, specifically Duchenne muscular dystrophy
Melbourne, Australia
Joined August 2020
$PER CEO Dr James Garner joined investors at Caulfield Racecourse yesterday to discuss the realities of early-stage cancer drug development - and the opportunity ahead for Percheron. #PercheronTx #oncology #immunotherapy #cancerresearch #clinicaltrials
0
0
0
WEBINAR REPLAY | In case you missed it, CEO Dr James Garner presents final Phase I results for HMBD-002 confirming an excellent safety profile and early signs of benefit in advanced cancers. Watch it here: https://t.co/iqEKLbMuWK $PER #PercheronTx #oncology #clinicaltrials
0
0
0
Final Phase I data for HMBD-002 show a strong safety profile and preliminary evidence of activity across multiple advanced cancers. These results will inform a planned Phase II trial in 2026. Read the ASX release: https://t.co/HEzuxsWHwj $PER #biotech #ASX
0
0
0
Percheron has reported strong progress in the development HMBD-002, including completion of technology transfer, initiation of Phase II manufacturing and team expansion. Join our webinar at 9am on October 7 for Phase I results: https://t.co/4qi4uhyRzw $PER #oncology #biotech #ASX
0
0
0
This #WDAD2023 Antisense Therapeutics stands alongside @JettFoundation in solidarity with families affected by Duchenne muscular dystrophy.
0
0
2
Positive new DMD Combination Therapy Data in mdx mice -
0
0
3
Antisense Therapeutics Limited will be attending the 9th Annual Parent Project Muscular Dystrophy conference in Dallas, Texas USA. Dr Gil Price will present clinical data on ATL1102 and the recently initiated Phase IIb clinical trial. #Duchenne #MuscularDystrophy #PPMDConference
0
0
4
MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD Key Highlights: Regulatory approvals in all four countries (UK, Turkey, Bulgaria and Australia) to conduct the Phase IIb trial. Three patients have now received a first dose. https://t.co/ILR7bsINkJ
0
0
3
First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial -
0
0
2
First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial -
0
0
3
First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial -
0
0
1
First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial -
0
0
1
Finance News Network - Investing in Healthcare and Life Sciences - Interview with Elliott Dean, a top shareholder in ANP -
0
0
1
Annual General Meeting Presentation Video -
0
1
1
World Duchenne Awareness Day - 7 September -
0
0
0
World Duchenne Awareness Day - 7 September -
0
1
1
World Duchenne Awareness Day - 7 September -
0
0
0
World Duchenne Awareness Day - 7 September -
0
0
0